Pharming GroupPHAR -1.69%76 Days Inventory is 889.14 as of Mar. 2026, which is 71% above its 10-year median of 518.94. GuruFocus rates PHAR with a GF Score™ of 76/100 and a GF Value™ of $14.56 (Fairly Valued). The stock has 1 warning sign investors should review. Among 638 Biotechnology companies, Pharming Group ranks worse than 82.76% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Pharming Group's Average Total Inventories for the
three
months ended in Mar. 2026 was $64.7 Mil. Pharming Group's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $6.6 Mil.
Hence, Pharming Group's Days Inventory for the
three
months ended in Mar. 2026 was 889.14.
The historical rank and industry rank for Pharming Group's Days Inventory or its related term are showing as below:
PHAR'
s Days Inventory Range Over the Past 10 Years
Min: 271.28 Med: 518.94 Max: 1335.86
Current: 541.37
During the past 13 years, Pharming Group's highest Days Inventory was 1335.86. The lowest was 271.28. And the median was 518.94.
PHAR's Days Inventory is ranked worse than 82.76% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs PHAR: 541.37
Pharming Group's Days Inventory
increased
from Mar. 2025 (630.79) to Mar. 2026 (889.14).
It might indicate that Pharming Group's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharming Group's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharming Group's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.89.
Pharming Group (NAS:PHAR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharming Group's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharming Group's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pharming Group Days Inventory Related Terms
Pharming Group Days Inventory Historical Data
* Premium members only.
The historical data trend for Pharming Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAR vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Pharming Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pharming Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a Days Inventory of 889.14 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharming Group and its competitors. This is 71% above median its historical median of 518.94. Over the past decade, Pharming Group's Days Inventory has ranged from 271.28 to 1,335.86. According to the industry distribution chart, Pharming Group ranks #528 out of 638 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Pharming Group's Days Inventory too high?
Pharming Group's current Days Inventory of 889.14 is 71% above median its 10-year median of 518.94. Over the past 10 years, this metric has ranged from a low of 271.28 to a high of 1,335.86. The Biotechnology industry median Days Inventory is 183.88. Pharming Group's value of 889.14 is 383.6% above this industry median. Based on the distribution chart, Pharming Group ranks #528 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharming Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #528 out of 638 companies for Days Inventory. This places Pharming Group in the lower half of its industry. The industry median Days Inventory is 183.88. Pharming Group's value of 889.14 is 383.6% above this benchmark. Historically, Pharming Group's own Days Inventory has ranged from 271.28 to 1,335.86 over the past decade. While the company's 10-year median is 518.94 vs. the industry median of 183.88, Pharming Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Days Inventory of 889.14 is 383.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Days Inventory is 889.14, which is 71% above median its own 10-year median of 518.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.56, compared to a current price of $13.66 — trading 6.2% below its estimated fair value. The current Days Inventory is 889.14, which is 71% above median its 10-year median of 518.94 and 383.6% above the Biotechnology industry median of 183.88. Pharming Group's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pharming Group (PHAR), the current Days Inventory is 889.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.66 is trading 6.2% below its estimated GF Value™ of $14.56.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Days Inventory: 889.14 (71% above median its 10-year median of 518.94)
GF Value™: $14.56 vs. price of $13.66 (6.2% below fair value)
Industry Position: 383.6% above the Biotechnology median (#528 of 638)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score
Get the complete analysis for PHAR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
